BIOMAT Database Logo BIOMAT Database Logo

Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? 1996

A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Rheumatism Foundation Hospital, Heinola, Finland.

OBJECTIVE To investigate the efficacy of intranasal salmon calcitonin (sCT) in treating axial bone loss in patients with rheumatoid arthritis (RA) taking low dose glucocorticoids. METHODS In this open, multicenter study 32 women with RA were treated one year with sCT 100 IU/day and calcium (Ca) 500 mg/day; 31 women were treated with Ca alone. Bone mineral density (BMD) was measured at the lumbar spine and proximal femur (femoral neck, Ward's triangle, trochanter) before sCT therapy and again after 6 and 12 months. RESULTS Among valid completers treated with sCT and Ca (n = 26), the mean BMD increased at the lumbar spine (L1-L4), femoral neck, and Ward's triangle. In contrast, valid completers treated with Ca (n = 23) showed bone loss at the spine (L1-L4), femoral neck, Ward's triangle, and trochanter area. The differences of the changes in BMD were statistically significant between these groups at the femoral neck, Ward's triangle, and trochanter. There were no significant differences between groups in bone loss over 12 months at the lumbar spine (L1-L4), although analysis of the upper segment (L1-L2) suggested some possible benefit of sCT. CONCLUSIONS Intranasal sCT (100 IU/day) appears to have beneficial effects on bone loss at the proximal femur in patients with active RA treated with low dose glucocorticoids for 12 months; longer studies are needed to exclude transient bone remodelling effects.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D002116 Calcitonin A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. Thyrocalcitonin,Calcitonin(1-32),Calcitrin,Ciba 47175-BA,Eel Calcitonin,Calcitonin, Eel,Ciba 47175 BA,Ciba 47175BA
D003710 Demography Statistical interpretation and description of a population with reference to distribution, composition, or structure. Demographer,Demographic,Demographic and Health Survey,Population Distribution,Accounting, Demographic,Analyses, Demographic,Analyses, Multiregional,Analysis, Period,Brass Technic,Brass Technique,Demographers,Demographic Accounting,Demographic Analysis,Demographic Factor,Demographic Factors,Demographic Impact,Demographic Impacts,Demographic Survey,Demographic Surveys,Demographic and Health Surveys,Demographics,Demography, Historical,Demography, Prehistoric,Factor, Demographic,Factors, Demographic,Family Reconstitution,Historical Demography,Impact, Demographic,Impacts, Demographic,Multiregional Analysis,Period Analysis,Population Spatial Distribution,Prehistoric Demography,Reverse Survival Method,Stable Population Method,Survey, Demographic,Surveys, Demographic,Analyses, Period,Analysis, Demographic,Analysis, Multiregional,Demographic Analyses,Demographies, Historical,Demographies, Prehistoric,Distribution, Population,Distribution, Population Spatial,Distributions, Population,Distributions, Population Spatial,Family Reconstitutions,Historical Demographies,Method, Reverse Survival,Method, Stable Population,Methods, Reverse Survival,Methods, Stable Population,Multiregional Analyses,Period Analyses,Population Distributions,Population Methods, Stable,Population Spatial Distributions,Prehistoric Demographies,Reconstitution, Family,Reconstitutions, Family,Reverse Survival Methods,Spatial Distribution, Population,Spatial Distributions, Population,Stable Population Methods,Technic, Brass,Technique, Brass
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic

Related Publications

A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
April 1992, Calcified tissue international,
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Low-dose glucocorticoid therapy in rheumatoid arthritis.
November 1995, Revue du rhumatisme (English ed.),
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
November 2005, Rheumatology international,
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis.
June 1992, Annals of the rheumatic diseases,
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study.
November 1993, Annals of internal medicine,
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy.
April 2010, Annals of the New York Academy of Sciences,
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis.
June 2012, Rheumatology (Oxford, England),
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Salmon calcitonin reduces vertebral bone loss in glucocorticoid-treated beagles.
June 1993, The American journal of physiology,
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Cirrhosis in patients with rheumatoid arthritis receiving low dose methotrexate.
October 1994, British journal of rheumatology,
A Kotaniemi, and H Piirainen, and L Paimela, and M Leirisalo-Repo, and K Uoti-Reilama, and P Lahdentausta, and P Ruotsalainen, and M Kataja, and E Väisänen, and P Kurki
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
January 2000, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,
Copied contents to your clipboard!